23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › CYTEK BIOSCIENCES INC. › 2023-2024

CYTEK BIOSCIENCES INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and CYTEK BIOSCIENCES INC.’s Form 8-K, filed June 11, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 164Asset managers, any item
  • 841Fund votes
  • June 5, 2024Meeting date

Results at a glance

Meeting of June 5, 2024: 4 items on CYTEK BIOSCIENCES INC.’s Form 8-K, filed June 11, 2024: 2 elected · 2 approved.

Dissent

Notable dissent: 1 director (13.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore CYTEK BIOSCIENCES INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by CYTEK BIOSCIENCES INC.

These tallies are CYTEK BIOSCIENCES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 11, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CYTEK BIOSCIENCES INC. — official shareholder meeting results, meeting held June 5, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Wenbin Jiang, Ph.D. 64,177,338---- 9,915,03623,010,427 87%Elected—
Elect Director: Michael Holder 70,298,785---- 3,793,58923,010,427 95%Elected—
2. Executive Compensation. On an advisory basis, compensation paid to the Company's named executive officers for the year ended December 31, 2023 63,537,38610,476,03978,949 --23,010,427 86%Approved—
3. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 94,116,5642,329,549656,688 ---- 98%Approved—

Source: CYTEK BIOSCIENCES INC., Form 8-K, filed with the SEC on June 11, 2024 — read the filing on EDGAR.

How asset managers voted at the CYTEK BIOSCIENCES INC. 2023-2024 meeting

164 asset managers disclosed a vote on at least one CYTEK BIOSCIENCES INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Michael Holder

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 70,298,785WITHHELD: 3,793,589
Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: To elect each of our two Class III director nominees to our Board of Directors for a three-year term, to hold office until our 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal: Michael Holder

CYTEK BIOSCIENCES INC.’s own tally for this item (“Elect Director: Michael Holder”): 70,298,785 for, 3,793,589 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class III director, to hold office until the Company's 2027 annual meeting of stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal:”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 33,376,751 for.

FOR
FOR: 33,376,751
Largest asset managers voting on “To elect each of our two Class III director nominees to our Board of Directors for a three-year term, to hold ” at CYTEK BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard11,709,2040 00For
BlackRock8,025,0090 00For
Brown Capital Management Mutual Funds4,548,3080 00For
Fidelity2,040,7150 00For
State Street1,099,2010 00For
Charles Schwab846,1760 00For
Dimensional798,9810 00For
Hartford552,6290 00For
Northwestern Mutual355,5110 00For
Nationwide325,6450 00For
TIAA302,4990 00For
Equitable284,6700 00For
Columbia Threadneedle268,3500 00For
First Trust248,0170 00For
Jackson National227,5350 00For
QUANTITATIVE MASTER SERIES LLC211,2170 00For
Invesco163,9690 00For
American Century127,6660 00For
Principal115,6550 00For
Lincoln Financial111,6760 00For
Prudential/PGIM103,2070 00For
BNY Mellon90,5130 00For
Thrivent84,9890 00For
Empower73,1550 00For
Catholic Responsible Investments Funds59,5420 00For

Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).

Elect Director: Wenbin Jiang, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 64,177,338WITHHELD: 9,915,036
Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: To elect each of our two Class III director nominees to our Board of Directors for a three-year term, to hold office until our 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal: Wenbin Jiang, Ph.D.

CYTEK BIOSCIENCES INC.’s own tally for this item (“Elect Director: Wenbin Jiang, Ph.D.”): 64,177,338 for, 9,915,036 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class III director, to hold office until the Company's 2027 annual meeting of stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal:”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 31,520,972 for, 1,773,549 withheld, 82,230 abstained.

FOR
FOR: 31,520,972ABSTAIN: 82,230WITHHOLD: 1,773,549
Largest asset managers voting on “To elect each of our two Class III director nominees to our Board of Directors for a three-year term, to hold ” at CYTEK BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard11,709,2040 00For
BlackRock8,025,0090 00For
Brown Capital Management Mutual Funds4,548,3080 00For
Fidelity2,040,7150 00For
State Street1,086,5500 012,651For
Charles Schwab846,1760 00For
Dimensional00 0798,981Withhold
Hartford552,6290 00For
Northwestern Mutual355,5110 00For
Nationwide302,0210 023,624Mixed
TIAA302,4990 00For
Equitable284,6700 00For
Columbia Threadneedle268,3500 00For
First Trust00 0248,017Withhold
Jackson National217,2740 10,2610For
QUANTITATIVE MASTER SERIES LLC211,2170 00For
Invesco163,9690 00For
American Century00 0127,666Withhold
Principal00 0115,655Withhold
Lincoln Financial102,4000 09,276Mixed
Prudential/PGIM103,2070 00For
BNY Mellon90,5130 00For
Thrivent00 084,989Withhold
Empower00 073,155Withhold
Catholic Responsible Investments Funds00 059,542Withhold

Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).

Executive Compensation. On an advisory basis, compensation paid to the Company's named executive officers for the year…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

86% Approved · of votes cast

FOR 86%AGAINST
FOR: 63,537,386AGAINST: 10,476,039

Prior year: 97.6% for (June 14, 2023 meeting) ▼ 11.8 pts

Details: description as filed, official tally, votes by 164 asset managers

Description as filed by funds: To vote, on an advisory basis, regarding the compensation of our named executive officers for the year ended December 31, 2023.

CYTEK BIOSCIENCES INC.’s own tally for this item (“2. Executive Compensation. On an advisory basis, compensation paid to the Company's named executive officers for the year ended December 31, 2023”): 63,537,386 for, 10,476,039 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “On an advisory basis, compensation paid to the Company's named executive officers for the year ended December 31, 2023 was approved based on the following results of voting:”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 56 asset managers voting on “To vote, on an advisory basis, regarding the compensation of our named executive officers for the year ended D” at CYTEK BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard11,709,2040 00For
BlackRock8,025,0090 00For
Brown Capital Management Mutual Funds04,548,308 00Against
Fidelity2,040,7150 00For
State Street1,095,6813,520 00For
Charles Schwab846,1760 00For
Dimensional798,9810 00For
Hartford552,6290 00For
Northwestern Mutual355,5110 00For
Nationwide25,462300,183 00Mixed
TIAA302,4990 00For
Equitable284,6700 00For
Columbia Threadneedle268,3500 00For
First Trust248,0170 00For
Jackson National227,5350 00For
QUANTITATIVE MASTER SERIES LLC211,2170 00For
Invesco0163,969 00Against
American Century0127,666 00Against
Principal115,6550 00For
Lincoln Financial111,6760 00For
Prudential/PGIM103,2070 00For
BNY Mellon90,5130 00For
Thrivent84,9890 00For
Empower073,155 00Against
Catholic Responsible Investments Funds059,542 00Against

Fund voting reports, all 56 managers: 28,046,073 for, 5,334,909 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 127 asset managers voting on “To vote, on an advisory basis, regarding the compensation of our named executive officers for the year ended D” at CYTEK BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
HHLR ADVISORS, LTD.6,657,0300 00For
BROWN CAPITAL MANAGEMENT LLC06,372,032 00Against
RA CAPITAL MANAGEMENT, L.P.3,870,0430 00For
State Street3,133,44937,239 00For
NEW YORK STATE COMMON RETIREMENT FUND2,947,9860 00For
BlackRock2,401,9010 00For
GEODE CAPITAL MANAGEMENT, LLC2,130,4380 00For
Wellington1,255,9370 00For
Charles Schwab900,1800 00For
Northern Trust808,48181 00For
MELLON INVESTMENTS Corp647,7840 00For
Impresa Management LLC517,7900 00For
PRINCIPAL GLOBAL INVESTORS516,4660 00For
Vanguard315,7600 00For
Nuveen305,6650 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC0255,163 00Against
Invesco0205,978 00Against
STATE OF WISCONSIN INVESTMENT BOARD195,3920 00For
Legal & General Investment Management America Inc0190,161 00Against
Connor, Clark & Lunn Investment Management Ltd.169,8190 00For
Rhumbline156,1473,949 00For
Goldman Sachs158,9720 00For
UBS0143,518 00Against
American Century0127,666 00Against
Prudential/PGIM112,2320 00For

Institutional-manager reports, all 127 managers: 28,493,948 for, 7,614,117 against, 184 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 94,116,564AGAINST: 2,329,549

Prior year: 100.0% for (June 14, 2023 meeting) ▼ 2.4 pts

Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

CYTEK BIOSCIENCES INC.’s own tally for this item (“3. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December”): 94,116,564 for, 2,329,549 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified based on the following results of voting:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 33,321,640 for, 59,542 against.

FOR
FOR: 33,321,640AGAINST: 59,542
Largest asset managers voting on “To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the ” at CYTEK BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard11,709,2040 00For
BlackRock8,025,0090 00For
Brown Capital Management Mutual Funds4,548,3080 00For
Fidelity2,040,7150 00For
State Street1,099,2010 00For
Charles Schwab846,1760 00For
Dimensional798,9810 00For
Hartford552,6290 00For
Northwestern Mutual355,5110 00For
Nationwide325,6450 00For
TIAA302,4990 00For
Equitable284,6700 00For
Columbia Threadneedle268,3500 00For
First Trust248,0170 00For
Jackson National227,5350 00For
QUANTITATIVE MASTER SERIES LLC211,2170 00For
Invesco163,9690 00For
American Century127,6660 00For
Principal115,6550 00For
Lincoln Financial111,6760 00For
Prudential/PGIM103,2070 00For
BNY Mellon90,5130 00For
Thrivent84,9890 00For
Empower73,1550 00For
Catholic Responsible Investments Funds059,542 00Against

Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).

Largest CYTEK BIOSCIENCES INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 131,272,929 shares outstanding at the time of that meeting.

Fund voting reports: top CYTEK BIOSCIENCES INC. shareholders by shares voted on “To vote, on an advisory basis, regarding the compensation of our named executive officers for…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 8.92%
2BlackRock 6.11%
3Brown Capital Management Mutual Funds 3.46%
4Fidelity 1.55%
5State Street 0.84%
6Charles Schwab 0.64%
7Dimensional 0.61%
8Hartford 0.42%
9Northwestern Mutual 0.27%
10Nationwide 0.25%
Institutional-manager reports: top CYTEK BIOSCIENCES INC. shareholders by shares voted on “To vote, on an advisory basis, regarding the compensation of our named executive officers for…”, 2023-2024
#Asset manager % of shares outstanding
1HHLR ADVISORS, LTD. 5.07%
2BROWN CAPITAL MANAGEMENT LLC 4.85%
3RA CAPITAL MANAGEMENT, L.P. 2.95%
4State Street 2.42%
5NEW YORK STATE COMMON RETIREMENT FUND 2.25%
6BlackRock 1.83%
7GEODE CAPITAL MANAGEMENT, LLC 1.62%
8Wellington 0.96%
9Charles Schwab 0.69%
10Northern Trust 0.62%

Reported CYTEK BIOSCIENCES INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

CYTEK BIOSCIENCES INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Entities affiliated with BlackRock, Inc.17,779,753 13.54%Proxy statement (DEF 14A), proxy filed April 25, 2024
BlackRock16,547,693 12.61%Form 13F, quarter ended March 31, 2024
Entities affiliated with Brown Capital12,016,325 9.15%Proxy statement (DEF 14A), proxy filed April 25, 2024
Entities affiliated with The Vanguard Group11,890,700 9.06%Proxy statement (DEF 14A), proxy filed April 25, 2024
Vanguard Group6,933,504 5.28%Form 13F, quarter ended March 31, 2024
Entities affiliated with RA Capital Management6,809,404 5.19%Proxy statement (DEF 14A), proxy filed April 25, 2024
Entities affiliated with HHLR Advisors, Ltd.6,657,030 5.07%Proxy statement (DEF 14A), proxy filed April 25, 2024
Ming Yan6,203,867 4.73%Schedule 13G, filed February 14, 2024
Wenbin Jiang5,702,130 4.34%Schedule 13G, filed February 14, 2024
State Street4,115,859 3.14%Form 13F, quarter ended March 31, 2024

Percentages above are of 131,272,929 shares outstanding, as reported by CYTEK BIOSCIENCES INC. on its Form 10-Q dated April 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At CYTEK BIOSCIENCES INC.'s shareholder meeting held June 5, 2024, in the 2023-2024 proxy season, 164 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 841 separate fund positions. On the most widely held item on that ballot — To vote, on an advisory basis, regarding the compensation of our named executive officers for… — CYTEK BIOSCIENCES INC.'s filing reports the proposal as approved, with 86% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CYTEK BIOSCIENCES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 11, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CYTEK BIOSCIENCES INC.’s 10-Q dated April 30, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

CYTEK BIOSCIENCES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “CYTEK BIOSCIENCES (CTKB) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/cytek-biosciences-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.